De-nesting and handling of fragile filled glass vials / prefilled syringes in sterile fill-finish
In sterile drug-product fill-finish (vials, prefilled syringes, cartridges, including lyophilized and high-potency products), thin-walled glass containers must be de-nested, presented, transferred to inspection, and capped without glass-to-glass contact that chips or cracks the container or generates particulates. Containers are rigid but brittle, dimensionally tight, and handled at high throughput; some carry cytotoxic/high-potent payloads where breakage is also a safety event. The task is hard because grip force must be precisely modulated on smooth, slippery glass and contact between adjacent vials must be detected before damage occurs. Note that BMS has been divesting its dedicated sterile injectable fill-finish sites (Anagni to Catalent in 2020; Phoenix, AZ to ROIS/ROVI closing in 2026), so this need is increasingly outside BMS's retained in-house footprint, though it persists in its biologics fill-finish (e.g., Manatí, Puerto Rico). We identified this through our own research; we have not confirmed the specifics with the customer directly. This page is our researched read — a starting point for that conversation.
What the task is
RESEARCHED · our reconstructionIn sterile drug-product fill-finish (vials, prefilled syringes, cartridges, including lyophilized and high-potency products), thin-walled glass containers must be de-nested, presented, transferred to inspection, and capped without glass-to-glass contact that chips or cracks the container or generates particulates. Containers are rigid but brittle, dimensionally tight, and handled at high throughput; some carry cytotoxic/high-potent payloads where breakage is also a safety event. The task is hard because grip force must be precisely modulated on smooth, slippery glass and contact between adjacent vials must be detected before damage occurs. Note that BMS has been divesting its dedicated sterile injectable fill-finish sites (Anagni to Catalent in 2020; Phoenix, AZ to ROIS/ROVI closing in 2026), so this need is increasingly outside BMS's retained in-house footprint, though it persists in its biologics fill-finish (e.g., Manatí, Puerto Rico).
Is this the actual task and sequence? What are the real tolerances, cycle rate, and reject criteria, and which steps are today's manual bottleneck? Answering these is what turns this from a researched signal into a validated use case.